Rhabdomyolysis is a life-threatening pathological process that must be treated as early as possible to avoid potentially life-threatening sequelae. Much of the evidence that informs the management of rhabdomyolysis is retrospective research, often reported from mass disasters, and many practices that have been implemented as standard treatment are based on small studies published more than 30 years ago. This issue reviews the current literature on rhabdomyolysis and provides recommendations for each phase of care, from the prehospital setting through disposition. The evidence is examined regarding the variety of therapies that are used to manage rhabdomyolysis, the potential for recognizing a genetic predisposition for the condition, and therapeutic recommendations that improve patient outcomes.
A 25-year-old man is brought to the ED in police custody. The police officer states that the man was found running in the street, screaming incoherently, and attacking passersby. The man is in 4-point hard restraints and is severely agitated, thrashing on the EMS gurney and yelling profanities. He is tachycardic but his other vital signs are normal. In order to safely transfer him to the hospital gurney, he is given 4 mg of midazolam IM and 20 mg of ziprasidone IM, after which he is sedated. You order laboratory studies, including a total CK level, and start 1 L of IV crystalloid fluids. A urine toxicology screen returns positive for methamphetamines. His CK level is 6000 U/L and the CMP is notable for a new AKI with a creatinine level of 2.0 mg/dL. You wonder how much fluid he should receive, and whether you should initiate any other medical interventions, such as alkalinization of the urine, loop diuretics, or mannitol . . .
A 40-year-old woman presents to the ED as a trauma activation following a rollover motor vehicle accident. She had been pinned under a vehicle and extrication took 40 minutes. She is tachycardic on arrival, but her vital signs are otherwise normal. She is alert, oriented, and protecting her airway, but has gross deformity of both of her thighs. Due to concern for possible crush syndrome, you order laboratory studies including CK levels, and administer 1 L of IV crystalloid fluids prior to sending her to the radiology department. Imaging reveals bilateral femur fractures. Her laboratory test results include a CK level of 40,000 U/L, a CMP notable for a new AKI with a creatinine level of 3.0 mg/dL, and a K+ level of 6.2 mEq/L. She is producing urine but it is dark. You consider reaching out to the on-call nephrologist about starting dialysis . . .
A 16-year-old girl presents to the ED with severe pain in both of her thighs after completing her first-ever spinning class today. Her vital signs are normal. On examination, her thighs are swollen, weak, and tender to palpation. Her laboratory test results are notable for a CK level of 1700 U/L and a creatinine level of 1.1 mg/dL. She asks if she will have to be admitted to the hospital, and you wonder whether she can be discharged safely . . .
Rhabdomyolysis is a complex disease process in which the breakdown of muscle cells leads to the release of intracellular contents, including myoglobin, creatine kinase (CK), and electrolytes. An excess of these contents in the extracellular space exerts toxic effects, resulting in a clinical syndrome that most notably affects the renal system, but has consequences on all organ systems. Rhabdomyolysis has a broad spectrum of clinical presentations. Data on the incidence of rhabdomyolysis are limited, primarily because of variability in the populations studied, but also due in part to a lack of prospective epidemiological studies and standardized definitions, along with a failure to diagnose and report milder cases. A 1994 study found a 0.074% incidence of rhabdomyolysis over a 7-year period among patients at a large university hospital.1 Conversely, a 2004 study that included routine CK screening for all trauma patients in the intensive care unit over a 5-year period found that rhabdomyolysis was present in 85% of the patients.2
Emergency clinicians should routinely consider rhabdomyolysis in the differential diagnosis of a number of presentations. With a range of possible etiologies, from infectious to iatrogenic to traumatic, as well as a range of symptom presentations, rhabdomyolysis can both resemble and exist as a consequence of many other disease processes. Rhabdomyolysis is a disease process in which mitigation of the devastating downstream effects depends on immediate intervention, ideally before the patient arrives to the emergency department (ED). Though the overall incidence of rhabdomyolysis is low in comparison to other disease processes that are routinely managed in the ED, the stakes for timely medical management are too high to dismiss.
There have been few prospective studies or randomized controlled trials to establish a gold standard for the treatment of rhabdomyolysis, and evidence for treatment modalities tends to be sourced from retrospective studies. To some extent, treatment is driven by dogma and tradition.3 A substantial portion of the research upon which clinicians base their management of rhabdomyolysis was published prior to 2000. This creates a somewhat mixed and outdated picture, with no formalized guidelines on standard of care.
This issue of Emergency Medicine Practice reviews the literature on the management of rhabdomyolysis and provides a set of evidence-based recommendations for managing this disease process, while steering away from treatments based on individual anecdote or institutional tradition.
A literature search was performed on MEDLINE®, The Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects. The term rhabdomyolysis emergency was searched in MEDLINE®. Citations were limited to English-language references from 2010 to 2020, with article types of controlled study, evidence-based medicine, major clinical study, meta-analysis, multicenter study, practice guideline, prospective study, randomized control trial, and retrospective study. This search produced 134 results, 23 of which were relevant. The term rhabdomyolysis was searched in the Cochrane Database of Systematic Reviews, producing 9 results, 1 of which was relevant. The term rhabdomyolysis emergency was searched in the Database of Abstracts of Reviews of Effects. Citations were limited to English-language references from 2010 to 2020, with an article type of peer-reviewed journals. This search produced 65 results, 20 of which were relevant. Finally, the bibliographies of the identified relevant articles were searched for other relevant sources, limited to peer-reviewed, English-language references from 1994 to 2020. This search produced an additional 37 studies. A total of 51 references were selected for inclusion in this review.
Based on standardized data quality scales, the bulk of the references fall within the categories of Level 3 to Level 5 evidence. The majority of references are retrospective studies, case series, or case reports; just 16 of the relevant references are randomized controlled trials or meta-analyses. The review identified by the Cochrane database search discloses that the quality of the meta-analysis was poor due to suboptimal methodology in the source studies. There are several possible reasons for this paucity of high-quality data. Individual, institution-based practices for the management of rhabdomyolysis may have produced acceptable patient outcomes in general, so further research into this topic is viewed as a low priority. Alternatively, while rhabdomyolysis is more common in specific subsets of patients (eg, critically ill trauma patients), it is seen less consistently in the ED overall, leading to only a handful of prospective studies with few participants, even in studies conducted over the course of several years. The incidence of rhabdomyolysis increases sharply during episodes of major mass disaster (particularly earthquakes), so the data collected in the setting of such disasters comprise the most robust source of information available on the topic. Unfortunately, by virtue of the chaotic and unanticipated nature of these incidents, careful design and implementation of high-quality prospective studies are not feasible, leaving a large body of literature drawn primarily from retrospective chart review. Bearing these limitations in mind, we have compiled an updated set of recommendations for the management of rhabdomyolysis based on the highest-quality data available. Recommendations for which evidence is scant are noted as such.
3. “I resuscitated my rhabdomyolysis patient with NS.”
We recommend the of use LR for fluid resuscitation rather than NS. While there has been some debate over this issue, the literature suggests that LR is excellent for maintenance of the appropriate alkaline urine pH, while large volumes of NS may cause iatrogenic hyperchloremic metabolic acidosis.
6. “My rhabdomyolysis patient has a 20G IV catheter. That should be sufficient access for his fluids.”
Because patients with rhabdomyolysis require resuscitation with large volumes of fluid, a single small-bore IV catheter is unlikely to be sufficient to meet the urine output goals. A large-bore IV catheter with fluids running wide open is superior. Depending on the severity of the patient’s rhabdomyolysis, multiple points of access may be considered in order to run fluids simultaneously.
8. “This is my patient’s second documented visit for rhabdomyolysis, but since the inciting etiology was clear in both cases, there’s no need to suspect a genetic disorder.”
The recent literature has demonstrated that underlying genetic predisposition to rhabdomyolysis is much more common than was previously assumed. Recurrent episodes of rhabdomyolysis are suggestive of a genetic predisposition, and a clear inciting cause does not rule out underlying genetic predisposition, as rhabdomyolysis is frequently multifactorial. While genetic testing will not be performed in the ED, it is worth discussing it with the patient so that outpatient testing can be considered in consultation with a primary care provider.
Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.
To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study is included in bold type following the references, where available. The most informative references cited in this paper, as determined by the authors, are highlighted.
Have questions or comments on the podcast? Write us at firstname.lastname@example.org
Don’t forget about the $50 Amazon card with any order over $300 through 12/31/20. Use code AMAZON20
Dr. Ashoo is a practicing emergency physician, board-certified in emergency medicine and clinical informatics. Join him as he takes you through the December 2020 issue of Emergency Medicine Practice: Rhabdomyolysis: Evidence-Based Management in the Emergency Department
Get quick-hit summaries of hot topics in emergency medicine. EMplify summarizes evidence-based reviews in a monthly podcast. Highlights of the latest research published in EB Medicine's peer-reviewed journals educate and arm you for life in the ED.
Gi Xiang Lee, MD; David K. Duong, MD, MS, FACEP
Ryan Knight, MD; Ram A. Parekh, MD
December 1, 2020
January 1, 2024
4 AMA PRA Category 1 Credits™, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2-A or 2-B Credits.
Date of Original Release: December 1, 2020. Date of most recent review: November 10, 2020. Termination date: December 1, 2023.
Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.
Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACEP Accreditation: Emergency Medicine Practice is approved by the American College of Emergency Physicians for 48 hours of ACEP Category I credit per annual subscription.
AAFP Accreditation: This Enduring Material activity, Emergency Medicine Practice, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 07/01/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 4 AAFP Prescribed credits.
AOA Accreditation: Emergency Medicine Practice is eligible for 4 Category 2-A or 2-B credit hours per issue by the American Osteopathic Association.
Specialty CME: Not applicable. For more information, please contact Customer Service.
Needs Assessment: The need for this educational activity was determined by a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, AHA, NCHS, and ACEP; and evaluation of prior activities for emergency physicians.
Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.
Goals: Upon completion of this activity, you should be able to: (1) demonstrate medical decision-making based on the strongest clinical evidence; (2) cost-effectively diagnose and treat the most critical presentations; and (3) describe the most common medicolegal pitfalls for each topic covered.
Discussion of Investigational Information: As part of the journal, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration–approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.
Faculty Disclosures: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Lee, Dr. Duong, Dr. Knight, Dr. Parekh, Dr. Mishler, Dr. Toscano, Dr. Jagoda, and their related parties report no relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.
Commercial Support: This issue of Emergency Medicine Practice did not receive any commercial support.
Earning Credit: Two Convenient Methods: (1) Go online to www.ebmedicine.net/CME and click on the title of the article. (2) Mail or fax the CME Answer And Evaluation Form (included with your June and December issues) to EB Medicine.
Hardware/Software Requirements: You will need a Macintosh or PC to access the online archived articles and CME testing.
Additional Policies: For additional policies, including our statement of conflict of interest, source of funding, statement of informed consent, and statement of human and animal rights, visit www.ebmedicine.net/policies.